What we do
Purpose
Hallmarks of aging
Portfolio
How we work
Who we are
Who we are
Join us
Join Us
People
Compliance
News
Contact
Second Rejuveron company transitions into clinical stage as first patient is dosed in trial of Endogena Therapeutics’ novel regenerative treatment for blindness caused by retinitis pigmentosa
Rejuveron has moved to its new incubator space in the Bio-Technopark in Schlieren-Zürich
Rejuveron will das Altern bremsen
We use cookies to analyse traffic and improve our services. Read more about our privacy policy
here
Accept
Decline